This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Chemical Specialty Stocks to Escape Industry Headwinds
by Anindya Barman
Softer end-market demand and customer de-stocking mar the prospects of the Zacks Chemicals Specialty industry. CE, AXTA and ESI are set to gain from self-help actions.
Celanese (CE) Gains on Acquisitions & Productivity Actions
by Zacks Equity Research
While Celanese (CE) faces headwinds from weaker demand and de-stocking, it benefits from productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Starts Carbon Capture & Utilization Operations
by Zacks Equity Research
Celanese (CE) is actively utilizing CCU to provide low-carbon alternatives for its Acetyl Chain and Engineered Materials products in an effort to assist clients worldwide.
Celanese (CE) Rallies 48% YTD: What's Driving the Stock?
by Anindya Barman
Celanese (CE) gains on its investments in organic projects, strategic acquisitions and productivity measures.
Celanese (CE) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Celanese (CE) gains on its productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Up 20.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Celanese (CE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Celanese (CE) Stock For Now
by Zacks Equity Research
Celanese (CE) gains on productivity actions, investments in high-return organic projects and acquisitions amid demand softness and customer de-stocking in certain end markets.
Celanese (CE) Up 25% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Celanese (CE) benefits from its productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Celanese (CE) surpasses earnings estimates in the third quarter on cost-reduction actions.
Celanese (CE) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Celanese (CE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Markets Rally as Fed Hints at The End of Rate Hikes While Macro Data Worsens
by Mayur Thaker
"Bad news is good news" for now, until the bad news keeps coming.
AdvanSix (ASIX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AdvanSix (ASIX) delivered earnings and revenue surprises of -3,700% and 12.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Celanese (CE) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese (CE) is expected to have benefited from its cost actions and contributions of acquisitions amid demand headwinds in certain markets in Q3.
Analysts Estimate Celanese (CE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Celanese (CE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albemarle (ALB) Completes MARBL Joint Venture Restructuring
by Zacks Equity Research
Albemarle (ALB) completes MARBL JV restructuring and takes full ownership of Kemerton facility.
Eastman Chemical (EMN) Benefits From Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) gains on cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
DuPont (DD) Unveils Low-Cyclics Silicone Soft Skin Adhesive
by Zacks Equity Research
The adhesive is created as part of DuPont's (DD) efforts to broaden its portfolio of solutions to support the expanding medical device market.
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
Celanese (CE) gains on productivity actions, investments in high-return organic projects and acquisitions amid demand softness and customer destocking in certain end markets.
Celanese (CE) Shares Up 21% YTD: What's Driving the Stock?
by Zacks Equity Research
Celanese (CE) benefits from its productivity measures, investments in organic projects and strategic acquisitions.
DuPont (DD) Benefits From Innovation and Spectrum Acquisition
by Zacks Equity Research
While DuPont (DD) faces headwinds from sluggishness in some markets, it benefits from innovation, the Spectrum Plastics acquisition and pricing and productivity actions.
PPG-Dutch University Partner to Build 1st Off-Road Solar Car
by Zacks Equity Research
PPG will supply PPG CoraChar fire protection coating to protect the vehicle's lithium (Li)-ion battery pack.
Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Celanese (CE) Closes Food Ingredients JV Formation With Mitsui
by Zacks Equity Research
Celanese (CE) monetizes the majority of its Food Ingredients business while maintaining the demand benefits of raw material integration with the Acetyl Chain.
Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Celanese (CE) Inks Deal With Population Council for VitalDose
by Zacks Equity Research
The VitalDose platform by Celanese (CE) Delivery Platform has a long history of application in approved parenteral drug options.